TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00439647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous (i.v.) once a year
Study: NCT01011127
Drug: pravastatin, rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02579967
Drug: Myeloablative Conditioning-Closed with amendment L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
Study: NCT03397004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
Study: NCT03642626
Drug: Cyclophosphamide 500 mg/m2; 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
Study: NCT03642626
Drug: Cyclophosphamide 500 mg/m2; 3 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
Study: NCT03642626
Drug: Cyclophosphamide 250 mg/m2; 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
Study: NCT03642626
Drug: Abecma, Intravenous Suspension
Normalized name: Abecma, intravenous suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
Study: NCT02513979
Drug: Angiotensin type II receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
Study: NCT03403556
Drug: Rosuvamibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
Study: NCT03403556
Drug: Monorova
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20mg qd for 24 weeks
Study: NCT03175835
Drug: Rosuvastatin 20 mg
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
Study: NCT03175835
Drug: Rosuvastatin 20 mg & CKD-519 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
Study: NCT03305471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching stock solution in bottle
Study: NCT03229096
Drug: Apatinib plus XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks.
Study: NCT02846532
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
Study: NCT00095017
Drug: MK0663, etoricoxib / Duration of Treatment: 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00212797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04072575
Drug: PP6M injection Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
Study: NCT00120822
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00245440
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg tablets; 2 tablets once daily (500 mg) for 3 days
Study: NCT00245440
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg tablets; 2 tablets once daily (800 mg) for 5 days
Study: NCT02473289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo on Day 1, 28 and 56.
Study: NCT00544115
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00544115
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04723732
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
Study: NCT03466411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as IV infusion.
Study: NCT02831998
Drug: ZuraPrep
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT03638258
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied once daily for 12 weeks
Study: NCT00359385
Drug: Alendronate 70mg weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70mg weekly
Study: NCT03489837
Drug: Levotuss
Normalized name: levothyroxine sodium Oral Tablet [Levotabs]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral taken
Study: NCT03150693
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, PO
Study: NCT03150693
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03150693
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03150693
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01249352
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
Study: NCT02852395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose; appearance matched to JNJ-48816274
Study: NCT01051635
Drug: LMP400
Normalized name: LMP400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
Study: NCT04012099
Drug: BMT101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection to each of 3 dose-groups.
Study: NCT01020747
Drug: Avastin® (bevacizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab injections (\~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
Study: NCT03028012
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Study: NCT01726517
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
Study: NCT04119050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as intravenous infusion
Study: NCT01474421
Drug: AQW051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive AQW051 in a high dose once daily orally for 28 days.
Study: NCT01474421
Drug: AQW051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive AQW051 in a low dose once daily orally for 28 days.
Study: NCT01474421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo once daily orally for 28 days.
Study: NCT03990519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive sodium chloride injection as placebo on Day 1.
Study: NCT02920021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT00688077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
Study: NCT04410354
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (total daily dose of 0 mg) for 10 days
Study: NCT02659384
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02659384
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02091297
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia
Study: NCT01024036
Drug: Best Supportive Care (BSC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
Study: NCT02865135
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
Study: NCT00574171
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
Study: NCT02805595
Drug: 23.4% Hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Injections
Study: NCT01778647
Drug: Stimulants plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
Study: NCT00796614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02514577
Drug: IDP-122 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lotion
Study: NCT02514577
Drug: IDP-122 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lotion. No active ingredient.
Study: NCT02675998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00043186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT00369603
Drug: Razadyne ER
Normalized name: Razadyne ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
Study: NCT00199160
Drug: BAY 43-9006
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02750553
Drug: SHR0534
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02750553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182583
Drug: Ba253MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182583
Drug: Ba253BINEB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00944996
Drug: SSRI; SNRI; TCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets or Pills, 1 or 2 per day, more than 2 month
Study: NCT00157690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg 1 x weekly for 12 months
Study: NCT02428218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric-coated microtablets
Study: NCT00725036
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00725036
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02413099
Drug: KBMSI-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
Study: NCT01916798
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
Study: NCT04235777
Drug: PDS01ADC
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT
Study: NCT04235777
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT
Study: NCT00334139
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: every 4 weeks for 4 months
Study: NCT01514630
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five grams of creatine monohydrate will be administered for eight weeks.
Study: NCT01591668
Drug: Single Ascending Dose Cohorts GS-9620
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Study: NCT01049984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet daily for 18 weeks
Study: NCT01974440
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT01974440
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT02753764
Drug: AZD7624
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02753764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01974440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
Study: NCT00254553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tubes of placebo per day
Study: NCT02712957
Drug: NEO6860
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRPV1 antagonist
Study: NCT01207752
Drug: Optive Lubricant Eye Drops
Normalized name: Refresh Optive Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear eye drop
Study: NCT02712957
Drug: NEO6860 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive substance
Study: NCT02712957
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAID
Study: NCT03084939
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Study: NCT02712957
Drug: Naproxen placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive substance
Study: NCT00162552
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with severe cirrhosis treated with a placebo
Study: NCT02414555
Drug: vasopressor
Normalized name: Vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
Study: NCT01016145
Drug: Antipsychotics
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
Study: NCT01016145
Drug: Antipsychotics
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
Study: NCT00629551
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, capsules
Study: NCT04677933
Drug: B: OLP-1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 patients will receive 10 µg OLP-1002 BIW OLP-1002
Study: NCT04677933
Drug: C: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 patients will receive Placebo BIW
Study: NCT02476058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Study: NCT03756922
Drug: FDL176
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTR potentiator
Study: NCT03685175
Drug: Formal study using hyperpolarized 13C-pyruvate injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)
Study: NCT03685175
Drug: Feasible study using hyperpolarized 13C-pyruvate injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy
Study: NCT03693391
Drug: Fluorine-18 Labeled [18F]-JNJ-64511070
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
Study: NCT01355822
Drug: PETN
Normalized name: PETN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythrithyltetranitrate: 80 mg orally twice a day
Study: NCT01355822
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, twice daily
Study: NCT01476124
Drug: GEn Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin enacarbil placebo
Study: NCT01381458
Drug: FSC
Normalized name: Dofscort 3%-1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone propionate / salmeterol xinofoate combination
Study: NCT01899066
Drug: Lucentis, chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
Study: NCT03175198
Drug: Prazaxa® Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
Study: NCT01899066
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
Study: NCT01344499
Drug: Ringer Lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: instillation of 1 liter of fluid at the end of laparoscopy
Study: NCT00634920
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
Study: NCT00634920
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
Study: NCT02101268
Drug: Best Available Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
Study: NCT04358068
Drug: Azithromycin (Azithro)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04358068
Drug: Placebo for Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02625753
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
Study: NCT02625753
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
Study: NCT01193218
Drug: Placebo (low dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day
Study: NCT01193218
Drug: Placebo (mid dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day
Study: NCT01193218
Drug: Placebo (high dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day